07/24/2026
CVS Health's has agreed to a settlement with the Federal Trade Commission that requires the pharmacy benefit manager to prioritize lower-cost prescription drugs on its standard formularies, offer plans without rebate-driven incentives, and pass negotiated drug rebates through to clients. The agreement resolves allegations that Caremark favored higher-cost insulin products to maximize rebates, contributing to higher drug prices. The settlement also includes new transparency requirements, protections against anti-competitive practices affecting independent pharmacy service providers, and provisions to recognize eligible purchases through TrumpRx toward deductibles when permitted.